While this peptide may complement your existing treatment plan, it should never replace evidence-based care or be used without monitoring
Low T 3 syndrome, defined as low levels of T3 with normal levels of TSH and FT4, is a condition that is associated with increased composite end point of ventricular assist device placement, heart transplantation, or death in patients with pre-existing HF (HR 2.12
Comparison to Other Senolytic Therapies To contextualise FOXO4-DRI, lets compare it to other senolytic approaches or peptides you may be aware of (helpful given your clinics peptide focus)
Realtime PCR was performed using TaqMan Universal Master Mix II, no UNG (Applied Biosystems PN 4440041) according to the protocol, using 1.33 l of undiluted cDNA per reaction and RNAspecific Taqman hydrolysis probes
Growth hormone fragment fat-loss protocol AOD-9604 (GH fragment 176-191) protocol guide: the lipolysis mechanism, the failed obesity trial, and the honest fat-loss picture A growth hormone fragment built to burn fat without raising IGF-1
Sher Mohammad, Consultant Anaesthetist(retired), STH NHS Foundation Trust, Sheffield Dr